Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Li, Zhaoyang ^a   Qi, Chen Feng ^a   Shin, Dong Mi ^a   Zingone, Adriana ^b   Newbery, Helen J ^c   Kovalchuk, Alexander L ^a   Abbott, Catherine M ^c   Morse III, Herbert C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ELONGATION FACTOR 1ALPHA; ELONGATION FACTOR 1ALPHA 2; JANUS KINASE; PROTEIN KINASE B; SHORT HAIRPIN RNA; STAT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; GENETIC ASSOCIATION; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMAN VERSUS ANIMAL COMPARISON; IN VITRO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMACYTOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION; TUMOR ESCAPE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BONE MARROW CELLS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, SERUM-FREE; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; JANUS KINASES; MICE; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PEPTIDE ELONGATION FACTOR 1; PLASMA CELLS; PLASMACYTOMA; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 77956292558     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010755     Document Type: Article

References (49)

1. Tomlinson VA, Newbery HJ, Wray NR, Jackson J, Larionov A, et al. (2005) Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer 5: 113.
2. Li R, Wang H, Bekele BN, Yin Z, Caraway NP, et al. (2006) Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach. Oncogene 25: 2628-2635.
3. Kulkarni G, Turbin DA, Amiri A, Jeganathan S, Andrade-Navarro MA, et al. (2007) Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer. Breast Cancer Res Treat 102: 31-41.
4. Grassi G, Scaggiante B, Farra R, Dapas B, Agostini F, et al. (2007) The expression levels of the translational factors eEF1A 1/2 correlate with cell growth but not apoptosis in hepatocellular carcinoma cell lines with different differentiation grade. Biochimie 89: 1544-1552.
5. Sun Y, Wong N, Guan Y, Salamanca CM, Cheng JC, et al. (2008) The eukaryotic translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic effects of ZNF217 in precursor cells of human ovarian carcinomas. Int J Cancer 123: 1761-1769.
6. Kido T, Lau YF (2008) The human Y-encoded testis-specific protein interacts functionally with eukaryotic translation elongation factor eEF1A, a putative oncoprotein. Int J Cancer 123: 1573-1585.
7. Cao H, Zhu Q, Huang J, Li B, Zhang S, et al. (2009) Regulation and functional role of eEF1A2 in pancreatic carcinoma. Biochem Biophys Res Commun 380: 11-16.
8. Knudsen SM, Frydenberg J, Clark BF, Leffers H (1993) Tissue-dependent variation in the expression of elongation factor-1 alpha isoforms: isolation and characterisation of a cDNA encoding a novel variant of human elongation-factor 1 alpha. Eur J Biochem 215: 549-554.
9. Lee S, Francoeur AM, Liu S, Wang E (1992) Tissue-specific expression in mammalian brain, heart, and muscle of S1, a member of the elongation factor-1 alpha gene family. J Biol Chem 267: 24064-24068.
10. Chambers DM, Peters J, Abbott CM (1998) The lethal mutation of the mouse wasted (wst) is a deletion that abolishes expression of a tissue-specific isoform of translation elongation factor 1alpha, encoded by the Eef1a2 gene. Proc Natl Acad Sci U S A 95: 4463-4468.
11. Browne GJ, Proud CG (2002) Regulation of peptide-chain elongation in mammalian cells. Eur J Biochem 269: 5360-5368.
12. Amiri A, Noei F, Jeganathan S, Kulkarni G, Pinke DE, et al. (2007) eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration. Oncogene 26: 3027-3040.
13. Ejiri S (2002) Moonlighting functions of polypeptide elongation factor 1: from actin bundling to zinc finger protein R1-associated nuclear localization. Biosci Biotechnol Biochem 66: 1-21.
14. Ruest LB, Marcotte R, Wang E (2002) Peptide elongation factor eEF1A-2/S1 expression in cultured differentiated myotubes and its protective effect against caspase-3-mediated apoptosis. J Biol Chem 277: 5418-5425.
15. Condeelis J (1995) Elongation factor 1 alpha, translation and the cytoskeleton. Trends Biochem Sci 20: 169-170.
16. Bektas M, Nurten R, Gurel Z, Sayers Z, Bermek E (1994) Interactions of eukaryotic elongation factor 2 with actin: a possible link between protein synthetic machinery and cytoskeleton. FEBS Lett 356: 89-93.
17. Gross SR, Kinzy TG (2005) Translation elongation factor 1A is essential for regulation of the actin cytoskeleton and cell morphology. Nat Struct Mol Biol 12: 772-778.
18. Chuang SM, Chen L, Lambertson D, Anand M, Kinzy TG, et al. (2005) Proteasome-mediated degradation of cotranslationally damaged proteins involves translation elongation factor 1A. Mol Cell Biol 25: 403-413.
19. Shamovsky I, Ivannikov M, Kandel ES, Gershon D, Nudler E (2006) RNAmediated response to heat shock in mammalian cells. Nature 440: 556-560.
20. Anand N, Murthy S, Amann G, Wernick M, Porter LA, et al. (2002) Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 31: 301-305.
21. Chang R, Wang E (2007) Mouse translation elongation factor eEF1A-2 interacts with Prdx-I to protect cells against apoptotic death induced by oxidative stress. J Cell Biochem 100: 267-278.
22. Qi CF, Zhou JX, Lee CH, Naghashfar Z, Xiang S, et al. (2007) Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells. Cancer Res 67: 2439-2447.
23. Zhang JQ, Okumura C, McCarty T, Shin MS, Mukhopadhyay P, et al. (2004) Evidence for selective transformation of autoreactive immature plasma cells in mice deficient in Fasl. J Exp Med 200: 1467-1478.
24. Lee CH, Melchers M, Wang H, Torrey TA, Slota R, et al. (2006) Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. J Exp Med 203: 63-72.
25. Shin DM, Shaffer DJ, Wang H, Roopenian DC, Morse HC, 3rd (2008) NOTCH is part of the transcriptional network regulating cell growth and survival in mouse plasmacytomas. Cancer Res 68: 9202-9211.
26. Morse HC, 3rd, McCarty T, Qi CF, Torrey TA, Naghashfar Z, et al. (2003) B lymphoid neoplasms of mice: characteristics of naturally occurring and engineered diseases and relationships to human disorders. Adv Immunol 81: 97-121.
27. Qi CF, Xiang S, Shin MS, Hao X, Lee CH, et al. (2006) Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas. Leuk Res 30: 153-163.
28. Akilesh S, Shaffer DJ, Roopenian D (2003) Customized molecular phenotyping by quantitative gene expression and pattern recognition analysis. Genome Res 13: 1719-1727.
29. Park ES, Shaughnessy JD, Jr., Gupta S, Wang H, Lee JS, et al. (2007) Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. BMC Genomics 8: 302.
30. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, et al. (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131-144.
31. Jeganathan S, Morrow A, Amiri A, Lee JM (2008) Eukaryotic elongation factor 1A2 cooperates with phosphatidylinositol-4 kinase III beta to stimulate production of filopodia through increased phosphatidylinositol-4,5 bisphosphate generation. Mol Cell Biol 28: 4549-4561.
32. Jeganathan S, Lee JM (2007) Binding of elongation factor eEF1A2 to phosphatidylinositol 4-kinase beta stimulates lipid kinase activity and phosphatidylinositol 4-phosphate generation. J Biol Chem 282: 372-380.
33. Panasyuk G, Nemazanyy I, Filonenko V, Negrutskii B, El'skaya AV (2008) A2 isoform of mammalian translation factor eEF1A displays increased tyrosine phosphorylation and ability to interact with different signalling molecules. Int J Biochem Cell Biol 40: 63-71.
34. Kim MJ, Si F, Kim SJ, Hong SB, Hwang JI, et al. (1999) The SH2-SH2-SH3 domain of phospholipase C-gamma1 directly binds to translational elongation factor-1alpha. Mol Cells 9: 631-637.
35. Lee S, LeBlanc A, Duttaroy A, Wang E (1995) Terminal differentiationdependent alteration in the expression of translation elongation factor-1 alpha and its sister gene, S1, in neurons. Exp Cell Res 219: 589-597.
36. Tomlinson VA, Newbery HJ, Bergmann JH, Boyd J, Scott D, et al. (2007) Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus. Br J Cancer 96: 1613-1620.
37. Qi CF, Shin DM, Li Z, Wang H, Feng J, et al. (2010) Anaplastic plasmacytomas: relationships to normal memory B cells and plasma cell neoplasms of immunodeficient nd autoimmune mice. J Pathol 221: 106-116.
38. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, et al. (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113: 5412-5417.
39. Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T (2006) Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-29-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci 97: 64-71.
40. Aaronson DS, Horvath CM (2002) A road map for those who don't know JAKSTAT. Science 296: 1653-1655.
41. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, et al. (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115.
42. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, et al. (2005) Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11: 623-629.
43. Ferrajoli A, Faderl S, Ravandi F, Estrov Z (2006) The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets 6: 671-679.
44. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, et al. (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93: 397-409.
45. Quintanilla-Martinez L, Kremer M, Specht K, Calzada-Wack J, Nathrath M, et al. (2003) Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol 162: 1449-1461.
46. Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, et al. (2000) Burkitt lymphoma in the mouse. J Exp Med 192: 1183-1190.
47. Morse HC, 3rd, Qi CF, Chattopadhyay SK, Hori M, Taddesse-Heath L, et al. (2001) Combined histologic and molecular features reveal previously unappreciated subsets of lymphoma in AKXD recombinant inbred mice. Leuk Res 25: 719-733.
48. Fredrickson TN, Lennert K, Chattopadhyay SK, Morse HC, 3rd, Hartley JW (1999) Splenic marginal zone lymphomas of mice. Am J Pathol 154: 805-812.
49. Potter M, Wiener F (1992) Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations. Carcinogenesis 13: 1681-1697.